Tyme Technologies — Technical Presentation (June 2018)
22 slides from Tyme Technologies's technical presentation, Jun 12, 2018
Slide 1: SM-88 First Human Study and Compassionate Use Program Clinical Analysis
SM-88 First Human Study (FHS) and Compassionate Use Program Clinical Analysis June 2018 NASDAQ: TYME Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk fac
Slide 3: First Human Study (FHS) and Compassionate Use Program
First Human Study (FHS) and Compassionate Use Program The First Human Study (FHS) Conducted with NY Presbyterian Lower Manhattan Initially designed as a 6-week monotherapy safety study; Protocol extended following early positive responses to therapy However it was not designed as a treat-to-progress
Slide 4: Key Takeaways
Key Takeaways Through These Two Programs, Confirmed Responses in 15 Different Cancers Some patients were on other therapies, however all patients were metastatic and progressing when SM-88 was initiated All results confirmed by blinded radiology review The findings of the Compassionate Use Program G
Slide 5: First Human Study (FHS): Patient Data
First Human Study (FHS): Patient Data (30 Patients with Monotherapy SM-88) June 2018 AGE ECOG PS METASTATIC CANCER TYPE PRIOR TRx PRIOR LINE OF SYSTEMIC THERAPY ORR ON SM-88 OS Mean 57.7 Mean 1.0 Breast 14 47% S= Surgery Median 1 CR 4 13% Average 33.8 Min 33 Average 1.6 Lung 5 17% C= Chemotherapy Av
Slide 6: FHS Baseline Demographics (n=30)
FHS Baseline Demographics (n=30) Patients were generally heavily pre-treated Baseline ECOG Performance Status was 1.6, with 14 (of 30) with a score of 2 or greater 33% of patients had documented systemic therapy following SM-88, 47% had any documented treatment including but not limited to radiation
Slide 7: Penultimate PFS From the First Human Study
Study Ended Without Disease Progression 15 / 23 Death Without Disease Progression 5 / 23 Disease Progression 3 / 23 Penultimate PFS Before SM-88 Penultimate PFS From the First Human Study Penultimate progression-free survival (PFS) is the comparison of PFS on SM-88 to the PFS of the last therapy Pri
Slide 8: First in Human Study: Overall Survival
First in Human Study (FHS): Overall Survival (30 Patients with Monotherapy SM-88) Data cutoff of 9/19/17 June 2018
Slide 9: FHS: Segment Analysis
FHS: Segment Analysis June 2018 Median survival for patients with ≧2 prior systemic drug therapies was ~2 years 5/11 (45%) of these patients demonstrated RECIST responses (CR=2, PR=3) Prior Systemic Therapies* Patients Average ECOG PS Median OS (months) Mean OS (months) Two or more (median = 3) 11 (
Slide 10: Safety Profile – In First Human Study and Prostate Trial
Safety Profile – In First Human Study and Prostate Trial No grade 2 or higher drug-related adverse events in the Phase Ib/II prostate cancer trial with >85 months of cumulative daily oral dosing experience June 2018 1.Includes all adverse events deemed as possibly, probably or definitely drug-relate
Slide 11: FHS: ECOG Performance Status Improvement
FHS: ECOG Performance Status Improvement All patients improved or maintained their ECOG PS within six weeks of starting SM-88 therapy Average ECOG PS improvement of 1.0 One patient who was bedridden (PS 4) at baseline was able to return to light work functions (PS 1) ECOG PS 2 patients had similar s
Slide 12: Compassionate Use Program: Patient Data
Compassionate Use Program: Patient Data (53 Evaluable Patients with at least 6 weeks of SM-88 Treatment) June 2018 2 AGE ECOG PS METASTATIC CANCER TYPE PRIOR TRx PRIOR LINE OF SYSTEMIC THERAPY ORR ON SM-88 OS Mean 50 Mean 1.0 Breast 11 21% S= Surgery Median 1 CR 8 15% Average 19.04 Min 7 Average 1.4
Slide 13: Compassionate Use Program: Overall Survival
Compassionate Use Program: Overall Survival (52 Evaluable Patients with at least 6 weeks of SM-88 Treatment and overall survival data ) June 2018 Data cutoff Feb 13, 2018; 10 patients alive at cutoff
Slide 14: FHS and Compassionate Use Patients: Overall Survival (Pooled)
FHS and Compassionate Use Patients: Overall Survival (Pooled data, n=83) June 2018 -Compassionate Use Patient -FHS Patient Bars represent individual patients, FHS data cutoff 9/19/17, Compassionate use program data cutoff 2/13/18
Slide 15: Complete Responses with SM-88: Overall Survival
Complete Responses with SM-88: Overall Survival (Pooled Data, N=83) June 2018 Overall Survival (OS) in Patients Achieving Complete Response There were twelve (12, 14% of overall) patients, with a range of cancers who achieved a CR with SM-88 treatment Median survival was 48.5 months Bars represent i
Slide 16: Partial Responses with SM-88: Overall Survival
Partial Responses with SM-88: Overall Survival (Pooled Data, N=83) June 2018 There were twenty-two (22, 27% of overall) patients, with a range of cancer who achieved a PR with SM-88 treatment Median survival was 13.7 months, 6 patients surviving over 5 years Overall Survival (OS) in Patients Achievi
Slide 17: Stable Disease with SM-88: Overall Survival
Stable Disease with SM-88: Overall Survival (Pooled Data, N=83) June 2018 There were thirty-three (33, 40% of overall) patients who achieved stable disease (SD) with SM-88 treatment Median survival was 17 months, 9 patients surviving over 3 years Overall Survival (OS) in Patients Achieving Stable Di
Slide 18: RECIST and Survival with SM-88
RECIST and Survival with SM-88 Apparently Not the Only Predictor of Overall Survival We believe RECIST criteria alone may not be the optimal assessment of benefit with SM-88 TYME is incorporating positron emission topography (PET) assessments in all future clinical trials June 2018 All Evaluable Pat
Slide 19: Clinical Efficacy Across Different Hormonal Status
Clinical Efficacy Across Different Hormonal Status (Pooled Data, 25 breast cancer patients of 83 evaluable) June 2018 Tumor responses generally consistent across different hormone status’ 21 of 25 patients had baseline hormone status available Hormonal Status Patients (n) CR PR SD ORR CBR Med OS (mo
Slide 20: Breast Cancer: Overall Survival (Pooled Data)
Breast Cancer: Overall Survival (Pooled Data, N=25 of 83) June 2018 Breast cancer was the largest cancer types across programs Overall Response Rate in this group was 44% Responses were seen across genetic sub-types and hormonal statuses Nine patients (36%) survived > than 3 years, Six (24%) survive
Slide 21: Triple-Negative Breast Cancer (Pooled Data)
Triple-Negative Breast Cancer (Pooled Data, N=5 of 83) June 2018 Between the FHS and Compassionate Use Program there were five patients with triple-negative breast cancer (TNBC) Two partial responses (PR) were observed (40%) Two patients experienced stable disease (SD) (40%) Median PFS 11.5 months B
Slide 22: State Street 7™ FLOOR
17 State Street 7™ FLOOR NEW YORK, NY 10005 NASDAQ: TYME [email protected] TYMEINC.COM
TYME Technologies — Technical Presentation (June 2018) on 6ix